New insight on the interaction between the immune system and tumor has identified the programmed death-1/programmed death-1 ligand pathway to be a key player in evading host immune response. The immune checkpoint modulator, nivolumab (BMS-936558/ONO-4538), is the first PD-1 inhibitor to gain regulatory approval, for the treatment of patients with unresectable melanoma. This review will discuss results from early phase studies of nivolumab in solid tumors including non-small cell lung cancer (NSCLC) as well as studies of nivolumab in combination with chemotherapy, other immune modulators and molecular targeted therapy in patients with NSCLC.
Bibliographical noteFunding Information:
RS, BCC and RAS have no conflicts of interest to declare. JBR has received research funding from Merck and BMS, is a paid consultant for Merck and is a compensated advisory board member for BMS.
RAS is supported by the National Research Foundation, Singapore and the Singapore Ministry of Education under its Research Centres of Excellence initiative.
All Science Journal Classification (ASJC) codes